梯瓦製藥工業TEVA
紐約證券 · USD
30.18
+0.38
(+1.28%)
收盤 12/12 04:59 (UTC+8)
盤後
30.19
+0.01
(+0.03%)
12/12 04:59 (UTC+8)
梯瓦製藥工業TEVA
30.18
+0.38
(+1.28%)
財務數據
損益表
- 38.78
- 38.50
- 44.57
- 38.19
- 41.64
- 43.32
- 42.29
- 38.91
- 41.76
- 44.80
- 5.93
- -0.72
- 15.77
- -14.31
- 9.03
- 4.03
- -2.38
- -7.99
- 7.32
- 7.28
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | |
營業收入淨額 | 4,480,000 | 4,176,000 | 3,891,000 | 4,229,000 | 4,332,000 | 4,164,000 | 3,819,000 | 4,457,000 | 3,850,000 | 3,878,000 |
營業成本 | 2,176,000 | 2,074,000 | 2,014,000 | 2,109,000 | 2,184,000 | 2,140,000 | 2,048,000 | 2,041,000 | 1,998,000 | 2,082,000 |
營業毛利 | 2,303,000 | 2,102,000 | 1,877,000 | 2,121,000 | 2,148,000 | 2,024,000 | 1,771,000 | 2,415,000 | 1,852,000 | 1,796,000 |
營業費用 | 1,422,000 | 1,647,000 | 1,356,000 | 2,149,000 | 2,198,000 | 2,031,000 | - | 1,660,000 | 1,474,000 | 2,426,000 |
研發費用 | 256,000 | 243,000 | 247,000 | 247,000 | 240,000 | 269,000 | 242,000 | 227,000 | 253,000 | 239,000 |
推銷及管理費用 | 980,000 | 964,000 | 924,000 | 960,000 | 903,000 | 938,000 | 887,000 | 896,000 | 836,000 | 877,000 |
非經常性項目費用 | 186,000 | 440,000 | 185,000 | 942,000 | 1,055,000 | 824,000 | 859,000 | 537,000 | 385,000 | 1,310,000 |
其他營業費用 | - | - | - | - | - | - | - | - | - | - |
營業利益 | 882,000 | 456,000 | 519,000 | -29,000 | -51,000 | -5,000 | -218,000 | 756,000 | 378,000 | -631,000 |
其他收入及費用 | - | - | - | - | - | - | - | - | - | - |
利息費用 | 237,000 | 252,000 | 225,000 | 218,000 | 225,000 | 233,000 | 250,000 | 249,000 | 280,000 | 268,000 |
稅前純益 | 646,000 | 203,000 | 294,000 | -247,000 | -324,000 | -246,000 | -467,000 | 507,000 | 98,000 | -900,000 |
所得稅 | 214,000 | -78,000 | 74,000 | 28,000 | 70,000 | 630,000 | -52,000 | 41,000 | -13,000 | -16,000 |
稅後純益 | 433,000 | 283,000 | 214,000 | -217,000 | -437,000 | -846,000 | -139,000 | 463,000 | 103,000 | -848,000 |
基本每股稅後盈餘(元) | 0.38 | 0.25 | 0.19 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.78 |
稀釋每股稅後盈餘(元) | 0.37 | 0.25 | 0.18 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.78 |
基本平均股數(千股) | 1147000.00 | 1147000.00 | 1159000.00 | 1133000.00 | 1133000.00 | 1133000.00 | 1123000.00 | 1121000.00 | 1121000.00 | 1120000.00 |
稀釋平均股數(千股) | 1164000.00 | 1161000.00 | 1159000.00 | 1133000.00 | 1133000.00 | 1133000.00 | 1123000.00 | 1137000.00 | 1135000.00 | 1120000.00 |
還原基本每股稅後盈餘(元) | 0.38 | 0.25 | 0.19 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.78 |
還原稀釋每股稅後盈餘(元) | 0.37 | 0.25 | 0.18 | -0.19 | -0.39 | -0.75 | -0.12 | 0.41 | 0.07 | -0.78 |
還原基本平均股數(千股) | 1,147,000 | 1,147,000 | 1,159,000 | 1,133,000 | 1,133,000 | 1,133,000 | 1,123,000 | 1,121,000 | 1,121,000 | 1,120,000 |
還原稀釋平均股數(千股) | 1,164,000 | 1,161,000 | 1,159,000 | 1,133,000 | 1,133,000 | 1,133,000 | 1,123,000 | 1,137,000 | 1,135,000 | 1,120,000 |
EBITDA(千元) | 1,132,000 | 707,000 | 757,000 | 298,000 | 117,000 | 276,000 | 331,000 | 1,019,000 | 653,000 | -296,000 |